Trials / Unknown
UnknownNCT04367402
COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)
COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Azienda Ospedaliera San Paolo · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The aims of this study is to define the genetic bases of COVID-19 related disease heterogeneity in frail population, to carry out a retrospective study on individuals w/wo symptoms to verify the reliability of a prognostic/diagnostic test based on IgM/IgG analysis and on the presence of genetic profiling and to explore the therapeutic potential of the modulation of ACE2 expression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | BioMedomics COVID-19 IgM-IgG Rapid Test | Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus |
Timeline
- Start date
- 2020-03-30
- Primary completion
- 2020-04-24
- Completion
- 2020-09-01
- First posted
- 2020-04-29
- Last updated
- 2020-04-30
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04367402. Inclusion in this directory is not an endorsement.